Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

10x Genomics (TXG) Other Operating Expenses (2018 - 2025)

10x Genomics' Other Operating Expenses history spans 6 years, with the latest figure at -$40.7 million for Q2 2025.

  • On a quarterly basis, Other Operating Expenses changed N/A to -$40.7 million in Q2 2025 year-over-year; TTM through Dec 2025 was -$49.9 million, a N/A change, with the full-year FY2025 number at -$49.9 million, changed N/A from a year prior.
  • Other Operating Expenses hit -$40.7 million in Q2 2025 for 10x Genomics, down from -$9.2 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for TXG hit a ceiling of $41.4 million in Q3 2023 and a floor of -$40.7 million in Q2 2025.
  • Historically, Other Operating Expenses has averaged $1.7 million across 3 years, with a median of -$330000.0 in 2021.
  • The widest YoY moves for Other Operating Expenses: up 37.09% in 2021, down 363.98% in 2021.
  • Tracing TXG's Other Operating Expenses over 3 years: stood at -$850000.0 in 2021, then soared by 2403.29% to $19.6 million in 2023, then tumbled by 307.89% to -$40.7 million in 2025.
  • Business Quant data shows Other Operating Expenses for TXG at -$40.7 million in Q2 2025, -$9.2 million in Q1 2025, and $19.6 million in Q4 2023.